ASX ANNOUNCEMENT

Australasian Lymphology Association Launches National Lymphoedema Awareness Month

Supports Wider L-Dex Access to ALA Members through 3M

Supports Sub-clinical Management

Tuesday, 12 March 2013

Brisbane, Australia. – ImpediMed Limited (“ImpediMed” or “Company”) is pleased to announce to shareholders that the Australasian Lymphology Association (ALA) has today launched National Lymphoedema Awareness Month to alert cancer patients and survivors of the hidden risk of developing lymphoedema from some cancer treatments.

In conjunction with the ALA and 3M Australia Pty Ltd (3M), the Company has marked the occasion by launching a special ALA program. This program is targeted at improving clinician access to the L-Dex® U400 device to assist in the adoption of ALA clinical guidelines. The ALA position statement, titled “Monitoring for the Early Detection of Breast Cancer Related Lymphoedema” was released in late October 2012.

The link to the recent ALA Position Statement and new promotional campaign can be found at: http://www.lymphoedema.org.au/

The ALA and 3M will provide training through their educational workshops on the use of the 3M™ Coban™ 2 Layer Compression System and the L-Dex U400 device for supporting early detection and management of sub-clinical lymphoedema. Bioimpedance Spectroscopy (BIS) was endorsed for its role in supporting the early detection of lymphoedema following breast cancer treatment in the recent ALA position statement “The early detection and management of sub-clinical lymphoedema may reduce the long term physical, functional and psychological effects caused by a later diagnosis and delayed management of the condition”. “The ALA endorses the use of bioimpedance spectroscopy (BIS) as a validated and reliable tool to enable early detection of breast cancer related lymphoedema (BCRL) of the arm”.

It is estimated that 400,000 Australians suffer from lymphoedema and there is no cure. In launching Lymphoedema Awareness Month, Dr Helen Mackie, a specialist lymphoedema medical consultant and President of the ALA said, “With early intervention being the primary means of limiting the impact lymphoedema has on patients, we aim to educate those most at risk about the early signs and symptoms so they can seek early diagnosis and treatment to minimise the impact the disorder might have on their health and their life.”

The ALA, 3M and ImpediMed promotion is relevant to the Company and our shareholders due to the potential broader access this promotion could deliver by expanding the clinical adoption of the L-Dex® U400 device to aid in the sub-clinical assessment of unilateral lymphoedema in cancer patients across both Australia and New Zealand.
ImpediMed announced on the 14 February 2013 it had entered into an exclusive agency agreement with 3M. 3M is responsible for the sale and co-marketing of ImpediMed’s lymphoedema products through its sales force in Australia and New Zealand.

Richard Carreon, ImpediMed CEO, stated “The new program is aimed at targeting wider adoption of BIS technology to assist clinicians to implement the lymphoedema management guidelines. The Company, ALA and 3M are optimistic about the impact this program could have in helping to prevent the progression of this significant health disorder in cancer patients.”

For further information contact: Richard Carreon, ImpediMed CEO  
T: +1 (858) 412-0200  
M: +1 (619) 309-6230

L-Dex is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to assist in the clinical assessment of unilateral lymphoedema of arm and leg in women and the leg in men by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au